Steroid hormone receptors represent a major target in drug discovery. As ligand inducible transcription factors, their activity can be modulated by small lipophilic molecules. Here we describe two panels of potent and selective luciferase reporter cell lines based on cells with low endogenous steroid receptor activity (U2OS). The panels contain reporter cell lines for estrogen receptors α and β, androgen, glucocorticoid, mineralocorticoid, and progesterone receptors. In the first panel, the activation of either synthetic, steroid response elements containing promoter or viral promoter is mediated by full-length steroid receptors. The second panel is based on the expression of the chimeric receptor, which was created by the replacement of the N-terminal part of the molecule by Gal4 DBD and that binds to multiple UAS sites in the reporter promoter. Both panels were extensively characterized by profiling 28 ligands in dose response manner in agonist and antagonist mode. We have analyzed and compared the responses to tested ligands from both panels and concluded that in general both systems generated similar qualitative response in terms of potency, efficacy, partial agonism/antagonism, mixed agonistic/antagonistic profiles and the rank of potencies was well conserved between both panels. However, we have also identified some artifacts introduced by the Gal4/LBD reporter assays in contrast to their full-length receptor reporter counterparts. Keeping in mind the advantages and drawbacks of each reporter format, these cell lines represent powerful and selective tools for profiling large compound libraries (HTS) and for detailed study of mechanisms by which compounds exert their biological effects.

Center for Chemical Genetics Institute of Molecular Genetics v v i Academy of Sciences of the Czech Republic Vídeňská Prague Czech Republic

See more in PubMed

Mangelsdorf D J, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans R M. The nuclear receptor superfamily: the second decade. Cell. 1995;83(6):835–839. PubMed PMC

Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview. Ann. Oncol. 2006;17( Suppl 10 ):59–62. PubMed

Lange C A, Sartorius C A, Abdel-Hafiz H, Spillman M A, Horwitz K B, Jacobsen B M. Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv. Exp. Med. Biol. 2008;630:94–111. PubMed

Chen Y, Sawyers C L, Scher H I. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 2008;8(4):440–448. PubMed PMC

Coghlan M J, Elmore S W, Kym P R, Kort M E. The pursuit of differentiated ligands for the glucocorticoid receptor. Curr. Top Med. Chem. 2003;3(14):1617–1635. PubMed

Fox E M, Davis R J, Shupnik M A. ERbeta in breast cancer--onlooker, passive player, or active protector? Steroids. 2008;73(11):1039–1051. PubMed PMC

Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, Omoto Y, Warner M, Gustafsson J A. Role of estrogen receptor beta in colonic epithelium. Proc. Natl. Acad. Sci. U S A. 2006;103(8):2959–2964. PubMed PMC

Drummond A E, Fuller P J. The importance of ERbeta signalling in the ovary. J. Endocrinol. 2010;205(1):15–23. PubMed

Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti C A, Gouvin L M, Sharma V M, Mercurio A M. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell. 2010;17(4):319–332. PubMed PMC

Robyr D, Wolffe A P, Wahli W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol. Endocrinol. 2000;14(3):329–347. PubMed

Sonneveld E, Jansen H J, Riteco J A, Brouwer A, van der Burg B. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol. Sci. 2005;83(1):136–148. PubMed

Wilkinson J M, Hayes S, Thompson D, Whitney P, Bi K. Compound profiling using a panel of steroid hormone receptor cell-based assays. J. Biomol. Screen. 2008;13(8):755–765. PubMed

Paguio A, Stecha P, Wood K W, Fan F. Improved dual-luciferase reporter assays for nuclear receptors. Curr. Chem. Genomics. 2010;(4):43–49. PubMed PMC

Escande A, Pillon A, Servant N, Cravedi J P, Larrea F, Muhn P, Nicolas J C, Cavailles V, Balaguer P. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochem. Pharmacol. 2006;71(10):1459–1469. PubMed

Paguio A, Almond B, Fan F, Stecha P, Garvin D, Wood M, Wood K V. pGL4 Vectors: A new generation of luciferase reporter vectors. Promega Notes. 2005;89:7–10.

Green S, Walter P, Kumar V, Krust A, Bornert J M, Argos P, Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986;320(6058):134–139. PubMed

Fagart J, Wurtz J M, Souque A, Hellal-Levy C, Moras D, Rafestin-Oblin M E. Antagonism in the human mineralocorticoid receptor. EMBO J. 1998;17(12):3317–3325. PubMed PMC

Di Croce L, Koop R, Venditti P, Westphal H M, Nightingale K P, Corona D F, Becker P B, Beato M. Two-step synergism between the progesterone receptor and the DNA-binding domain of nuclear factor 1 on MMTV minichromosomes. Mol. Cell. 1999;4(1):45–54. PubMed

Grossmann C, Scholz T, Rochel M, Bumke-Vogt C, Oelkers W, Pfeiffer A F, Diederi ch S, Bahr V. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur. J. Endocrinol. 2004;151(3):397–406. PubMed

Sonneveld E, Riteco J A, Jansen H J, Pieterse B, Brouwer A, Schoonen W G, van der Burg B. Comparison of in vitro and in vivo screening models for androgenic and estrogenic activities. Toxicol. Sci. 2006;89(1):173–187. PubMed

Quinkler M, Meyer B, Bumke-Vogt C, Grossmann C, Gruber U, Oelkers W, Diederich S, Bahr V. Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor. Eur. J. Endocrinol. 2002;146(6):789–799. PubMed

Hyder S M, Chiappetta C, Stancel G M. Interaction of human estrogen receptors alpha and beta with the same naturally occurring estrogen response elements. Biochem. Pharmacol. 1999;57(6):597–601. PubMed

Cowley S M, Parker M G. A comparison of transcriptional activation by ER alpha and ER beta. J .Steroid Biochem. Mol. Biol. 1999;69(1-6):165–175. PubMed

Loven M A, Wood J R, Nardulli A M. Interaction of estrogen receptors alpha and beta with estrogen response elements. Mol. Cell Endocrinol. 2001;181(1-2):151–163. PubMed

Rundlett S E, Wu X P, Miesfeld R L. Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol. Endocrinol. 1990;4(5):708–714. PubMed

Jenster G, van der Korput H A, van Vroonhoven C, van der Kwast T H, Trapman J, Brinkmann A O. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. 1991;5(10):1396–1404. PubMed

Simental J A, Sar M, Lane M V, French F S, Wilson E M. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem. 1991;266(1):510–518. PubMed

Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol. Cell. Biol. 1999;19(9):6085–6097. PubMed PMC

He B, Kemppainen J A, Wilson E M. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 2000;275(30):22986–22994. PubMed

Zhang J H, Chung T D, Oldenburg K R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999;4(2):67–73. PubMed